封面
市場調查報告書
商品編碼
1806539

藥用輔料市場按類型、配方、功能、最終用戶和分銷管道分類—2025-2030 年全球預測

Pharmaceutical Excipient Market by Type, Formulation, Function, End-User, Distribution Channel - Global Forecast 2025-2030

出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年藥用輔料市場價值將達到92.2億美元,2025年成長至98.9億美元,複合年成長率為7.73%,到2030年將達到144.2億美元。

主要市場統計數據
基準年2024年 92.2億美元
預計2025年 98.9億美元
預測年份 2030 144.2億美元
複合年成長率(%) 7.73%

了解藥用輔料在全球藥物開發和製造過程中的重要角色和演變

藥用輔料已從惰性物質演變為重要的功能性成分,影響著現代劑型的安全性、有效性和病患體驗。輔料的選擇和設計影響藥物穩定性、釋放曲線和生物有效性等關鍵參數。近年來,藥用輔料產業已轉向先進的輔料技術,以實現控制釋放、提高溶解度以及與複雜活性藥物成分(包括新型小分子化合物和生物療法)的相容性。

檢驗近期顛覆性創新和新興創新,它們正在重新定義藥用輔料在研究和製造領域的格局

近年來,在技術進步和治療需求不斷變化等因素的共同推動下,藥用輔料領域發生了重大變化。數位化工具和人工智慧平台已開始徹底改變輔料的發現和最佳化,實現了物理化學相互作用的預測建模和電腦製劑篩檢。這些創新有助於加快開發週期,並減少對試驗試驗的依賴。

評估近期美國關稅政策如何改變全球出口供應鏈和製藥業的籌資策略

美國近期實施的賦形劑進口關稅政策引發了全球供應鏈的重大重組。某些化學中間體和原料的關稅上調帶來了額外的成本壓力,迫使製造商重新評估籌資策略和物流框架。這些發展趨勢凸顯了供應鏈視覺性的重要性,因為相關人員正在努力降低關稅上漲和潛在瓶頸帶來的風險。

全面的市場細分洞察,涵蓋類型、配方、功能、最終用戶概況和分銷管道動態

對藥用輔料市場進行詳細研究後發現,市場按類型細分,包括無機輔料和有機輔料。無機輔料包括碳酸鈣、磷酸鈣、岩鹽礦物和金屬氧化物等化合物。這些材料在固態劑型中扮演稀釋劑、緩衝劑和結構支撐的作用。在有機輔料中,纖維素衍生物、澱粉和糖等碳水化合物提供多種功能,從基質形成劑到崩壞。源自天然脂肪和油的油脂化學品產品,如脂醇類、甘油和礦物硬脂酸鹽,有助於潤滑和控制水分。石油化學衍生物,如丙烯酸聚合物、乙二醇、礦物碳氫化合物和聚維酮,具有成膜、增溶和穩定作用。

繪製美洲、中東和非洲以及亞太地區藥用輔料市場的區域趨勢和成長動力

在美洲,藥用輔料產業得到了成熟研究中心和製造中心的支持。監管機構正在簡化輔料分類指南,為新型載體的核准途徑。在美國,公共機構與產業聯盟之間的合作正在加速功能性輔料庫的開發,從而能夠快速識別適用於新型劑型的材料。加拿大和拉丁美洲市場提供了互補的機會,當地製造業的興起和有利的貿易協定正在擴大區域供應網路。因此,該地區的公司可以受益於強大的基礎設施,這些基礎設施支援創新、品質保證和高效分銷。

重點介紹塑造競爭格​​局的主要企業、策略聯盟和技術進步

領先的輔料公司採取了多種策略,以增強其競爭地位並在整個醫藥價值鏈中獲取價值。策略性併購使他們能夠增強能力並擴展產品系列。同時,與學術實驗室和特種化學品製造商的技術合作加速了創新,使得能夠共同開發用於複雜生技藥品製劑的先進載體和新型給藥平台。

來自行業領導者的策略行動要點和最佳實踐指南,以克服未來挑戰並利用領先創新

為了在技術快速進步和監管環境不斷變化的市場中取得成功,產業領導者應優先投資輔料創新平台。採用高通量篩檢和分子建模等整合發現工具,可以幫助企業加快識別能夠解決特定穩定性、溶解度和釋放挑戰的功能性載體。強調材料科學家、製劑專家和監管團隊之間的跨職能協作,可以簡化開發流程,並提高通過監管審查的幾率。

調查方法、資料來源、檢驗方法和研究中使用的分析框架的詳細描述

我們的調查方法結合了多層次的視角,全面涵蓋了藥用輔料的產業格局。初始階段的二次研究涵蓋了嚴謹的二次研究,利用權威的科學出版物、監管指南、專利分析和行業白皮書來建立基礎見解。這項案頭研究提供了關於輔料分類、新興技術以及影響該領域的政策框架的背景資訊。

綜合主要發現和策略意義,為藥用輔料產業的相關人員提供明智的決策

摘要:藥用輔料領域正處於創新、監管格局和供應鏈韌性的交匯點。輔料已超越其傳統的惰性角色,成為確保各種劑型穩定性、生物有效性和以患者為中心的設計的策略推動者。人工智慧、連續製造和永續生產方法等技術進步,正在推動新一波功能性載體的出現,以適應不斷發展的治療模式。

目錄

第1章:前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 矽基潤滑劑的進展,最佳化了 GMP 條件下高速片劑製造的粉末流動
  • 患者對天然配方的需求不斷增加,將推植物來源和潔淨標示輔料的轉變
  • 使用共加工輔料來提高片劑生產中直接壓片配方的效率
  • 透過在積層製造中整合即時分析技術進行持續的製程檢驗
  • 加強對設計品質的監管,以規範全球市場的積層生產
  • 生物分解性聚合物輔料的出現,有助於實現永續性目標並減少對環境的影響
  • 供應鏈多角化策略緩解藥用輔料市場原料短缺

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章:藥用輔料市場(按類型)

  • 無機
    • 碳酸鈣
    • 磷酸鈣
    • 硫酸鈣
    • 岩鹽
    • 金屬氧化物
  • 有機的
    • 碳水化合物
      • 纖維素
      • 澱粉
    • 油脂化工產品
      • 脂醇類
      • 甘油
      • 礦物硬脂酸鹽
    • 石化產品
      • 丙烯酸聚合物
      • 乙二醇
      • 礦物碳氫化合物
      • 聚維酮
    • 蛋白質

9. 藥用輔料市場(依配方)

  • 口服製劑
    • 硬明膠膠囊
    • 液體製劑
    • 軟膠囊
    • 藥片
  • 腸外製劑
  • 局部製劑

第 10 章:藥用輔料市場(按功能)

  • 黏合劑
  • 被覆劑
  • 著色劑
  • 崩壞
  • 乳化劑
  • 填充劑和稀釋劑
  • 調味劑和甜味劑
  • 潤滑劑和助流劑
  • 防腐劑
  • 懸浮劑和增稠劑

第 11 章:藥用輔料市場(依最終用戶分類)

  • 生物製藥公司
  • 契約製造組織
  • 製藥公司
  • 研究所

第 12 章:藥用輔料市場(依分銷通路)

  • 離線
  • 線上

13.美洲藥用輔料市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 歐洲、中東和非洲地區藥用輔料市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15. 亞太藥用輔料市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • ABITEC Corporation
    • Actylis
    • Archer Daniels Midland Company
    • ARMOR PROTEINES SAS by Savencia Group
    • Asahi Kasei Corporation
    • Ashland Inc.
    • BASF SE
    • BIOGRUND GmbH
    • Chemische Fabrik Budenheim KG by Geschwister Oetker Beteiligungen KG
    • Clariant AG
    • Colorcon Inc.
    • Corel Pharma Chem Private Limited
    • Croda International Plc
    • Darling Ingredients, Inc.
    • DFE Pharma GmbH & Co KG by Royal FrieslandCampina NV
    • DuPont de Nemours, Inc.
    • Evonik Industries AG
    • Fuji Chemical Industries Co., Ltd.
    • GATTEFOSSE SAS
    • Innophos Holdings, Inc. by Iris Parent LLC
    • International Flavors & Fragrances Inc.
    • JRS PHARMA GmbH+Co. KG
    • Kerry Group PLC
    • Lipoid GmbH
    • Lubrizol Corporation
    • L'AIR LIQUIDE SA
    • Mallinckrodt plc
    • MEGGLE GmbH & Co. KG
    • Merck KGaA
    • Nagase & Co., Ltd.
    • Nipon Soda Co., Ltd.
    • NOF Corporation
    • Omya International AG
    • Peter Greven GmbH & Co. KG
    • Roquette Freres SA
    • Shin-Etsu Chemical Co., Ltd.
    • Solvay SA
    • SPI Pharma, Inc.
    • Sumitomo Seika Chemicals Company, Limited
    • Thermo Fisher Scientific Inc.
    • Vanderbilt Minerals LLC

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-030EE48515E2

The Pharmaceutical Excipient Market was valued at USD 9.22 billion in 2024 and is projected to grow to USD 9.89 billion in 2025, with a CAGR of 7.73%, reaching USD 14.42 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 9.22 billion
Estimated Year [2025] USD 9.89 billion
Forecast Year [2030] USD 14.42 billion
CAGR (%) 7.73%

Navigating the Critical Role and Evolution of Pharmaceutical Excipients in Modern Drug Development and Manufacturing Processes Worldwide

Pharmaceutical excipients have evolved from inert substances to essential functional components that shape the safety, efficacy, and patient experience of modern dosage forms. Their selection and design influence critical parameters such as drug stability, release profile, and bioavailability. In recent years, the industry has witnessed a shift toward advanced excipient technologies that enable controlled release, improved solubility, and compatibility with complex active pharmaceutical ingredients, including novel small molecules and biological therapies.

Moreover, the regulatory landscape has placed increasing emphasis on the quality by design paradigm, mandating a systematic approach to excipient evaluation and classification. This trend has driven greater scrutiny of raw material sources, manufacturing processes, and impurity profiles. As a result, formulation scientists and quality teams have begun to integrate advanced analytical methods and robust risk assessment frameworks to ensure consistent performance and compliance.

Furthermore, supply chain resilience has become a critical consideration, as disruptions can cascade into delays and increased costs. Strategic sourcing strategies now incorporate supplier audits, dual sourcing models, and digital traceability solutions to maintain continuity. In this context, understanding the multifaceted role of excipients is paramount for stakeholders seeking to optimize formulation performance and operational efficiency across all stages of the drug development lifecycle.

As pharmaceutical development embraces patient-centric approaches, excipient innovation also addresses factors such as taste masking, ease of administration, and device compatibility. Novel polymeric carriers, lipid-based systems, and multifunctional granulation excipients have emerged to support personalized dosing, pediatric formulations, and fixed-dose combinations. Consequently, excipient selection has become a strategic differentiator, driving competitive advantage and enabling accelerated time to market for breakthrough therapies.

Examining the Recent Disruptions and Emerging Innovations Redefining the Pharmaceutical Excipient Landscape Across Research and Production

Recent years have witnessed transformative shifts within the pharmaceutical excipient landscape, driven by a confluence of technological advancements and evolving therapeutic demands. Digital tools and artificial intelligence platforms have begun to revolutionize excipient discovery and optimization, enabling predictive modeling of physicochemical interactions and in silico formulation screening. These innovations facilitate accelerated development cycles and reduce reliance on trial-and-error experimentation.

In parallel, continuous manufacturing processes have gained traction, moving beyond traditional batch operations toward integrated, sensor-driven production lines. This shift enhances process control, reduces material waste, and supports real-time release testing for excipient blends. As a result, manufacturers are able to maintain consistent product quality while operating with greater agility and responsiveness to market requirements.

Sustainability has also emerged as a pivotal driver of change, with stakeholders prioritizing green chemistry principles and renewable raw materials. Biodegradable polymers, plant-derived carriers, and solvent-free production techniques are gaining prominence in response to environmental regulations and corporate responsibility agendas. Consequently, the excipient sector is aligning its innovation roadmap with global sustainability targets, fostering partnerships across academia, biotechnology firms, and contract manufacturing organizations.

Moreover, the increasing complexity of biologics and novel modalities, such as cell and gene therapies, has underscored the need for excipients that provide stabilization, cryoprotection, and targeted release capabilities. This confluence of factors is reshaping research priorities and investment strategies, heralding a new era of excipient design that blends functionality with regulatory compliance and environmental stewardship.

Assessing How Recent US Tariff Policies Have Altered Global Excipent Supply Chains and Procurement Strategies in the Pharmaceutical Sector

With the recent implementation of United States tariff policies affecting excipient imports, global supply chains have undergone significant realignment. Tariff increases on select chemical intermediates and raw materials have introduced additional cost pressures, prompting manufacturers to reevaluate sourcing strategies and logistical frameworks. This dynamic has heightened the importance of supply chain visibility, as stakeholders seek to mitigate exposure to escalating duties and potential bottlenecks.

Dependence on international suppliers for key excipient components exposed vulnerabilities in just-in-time inventory models. In response, many organizations have initiated dual sourcing arrangements and localized procurement partnerships to diversify risk. Furthermore, a renewed emphasis on supplier qualification and performance monitoring has emerged, ensuring that alternative suppliers can meet stringent quality and regulatory standards.

As a result, procurement teams are collaborating more closely with formulation scientists and quality assurance professionals to align sourcing decisions with product performance criteria. Strategic stockpiling, forward purchasing agreements, and closer engagement with logistics providers are being employed to safeguard continuity. Additionally, some firms are exploring nearshoring opportunities to reduce transit times and lower exposure to customs delays.

Despite these challenges, the industry has demonstrated resilience by leveraging digital supply chain management platforms and advanced analytics. Predictive demand forecasting and scenario planning tools are enabling companies to anticipate disruptions and adjust procurement strategies in real time. This collective response underscores the sector's capacity to adapt to evolving trade policies while maintaining uninterrupted production of life-saving therapies.

Comprehensive Unraveling of Market Segmentation Insights Spanning Type, Formulation, Function, End-User Profiles, and Distribution Channel Dynamics

An in-depth examination of the pharmaceutical excipient market reveals a nuanced segmentation by type that encompasses both inorganic and organic classes. Inorganic excipients include compounds such as calcium carbonate, calcium phosphate, halite minerals, and metal oxides. These materials serve as diluents, buffering agents, and structural supports within solid dosage forms. On the organic side, carbohydrates such as cellulose derivatives, starches, and sugars provide diverse functionalities, ranging from matrix formers to disintegrants. Oleochemical products derived from natural fats, including fatty alcohols, glycerin, and mineral stearates, contribute to lubrication and moisture control. Petrochemical derivatives include acrylic polymers, glycols, mineral hydrocarbons, and povidones, offering film-forming, solubilizing, and stabilizing properties.

Formulation-based segmentation further refines the landscape by distinguishing between oral, parenteral, and topical dosage forms. Within oral formulations, hard gelatin and soft gelatin capsules, tablets, and liquid preparations each demand tailored excipient profiles to ensure dose uniformity, stability, and patient compliance. Parenteral applications necessitate excipients that meet rigorous injectable standards, providing sterility, isotonicity, and compatibility with sensitive therapeutic agents. Topical formulations, including creams, gels, and transdermal systems, rely on specific carriers and emulsifying systems to facilitate drug permeation and user acceptability.

Functional segmentation underscores the diverse roles played by excipients across formulation development. Binders impart cohesion to granules and tablets, whereas coating agents enhance stability and palatability. Disintegrants accelerate tablet breakdown, and emulsifying agents stabilize heterogeneous mixtures. Fillers and diluents establish bulk, while flavoring agents and sweeteners improve organoleptic properties. Lubricants and glidants optimize processing efficiency, and preservatives protect against microbial growth. Suspending and viscosity agents further ensure uniformity and performance in semi-solid and liquid preparations.

Finally, the market is shaped by its end users and distribution channels. Biopharmaceutical companies, contract manufacturing organizations, traditional pharmaceutical manufacturers, and research laboratories each leverage excipient technologies to meet specialized objectives. Distribution occurs through both offline channels, encompassing direct sales and distributor partnerships, and online platforms that streamline procurement and broaden access. Together, these segmentation insights provide a comprehensive framework for understanding the diverse drivers shaping excipient selection and utilization.

Mapping Regional Trends and Growth Drivers Across the Americas, Europe Middle East & Africa, and Asia-Pacific Pharmaceutical Excipent Markets

Across the Americas, the pharmaceutical excipient sector is anchored by well-established research hubs and manufacturing centers. Regulatory authorities have streamlined excipient classification guidelines, facilitating smoother approval pathways for novel carriers. In the United States, collaboration between public agencies and industry consortia has accelerated the development of functional excipient libraries, enabling rapid identification of suitable materials for new dosage forms. Canada and Latin American markets offer complementary opportunities, with emerging local production initiatives and favorable trade agreements expanding regional supply networks. Consequently, organizations in this geography benefit from a robust infrastructure that supports innovation, quality assurance, and efficient distribution.

Transitioning to Europe, the Middle East & Africa region reveals a complex tapestry of regulatory environments and market dynamics. European Union directives emphasize stringent excipient quality standards, driving harmonization efforts that reduce duplication of testing and facilitate cross-border commerce. In the Middle East, government-led pharmaceutical clusters are fostering local value creation, while African markets are gradually enhancing their regulatory frameworks to attract foreign investment. These developments underscore the strategic importance of understanding diverse regulatory nuances and forging partnerships with regional stakeholders to navigate this multifaceted landscape.

In contrast, the Asia-Pacific region exhibits a blend of cost-effective manufacturing capacity and rapidly evolving regulatory oversight. Leading economies in East Asia have invested heavily in excipient R&D, particularly in advanced polymer systems and functional carbohydrates. South Asian countries continue to offer competitive production costs, underpinned by skilled workforce capabilities. Regulatory authorities across the region are increasingly aligning with international standards, while digital tools for quality monitoring and traceability are gaining adoption. This dynamic environment positions Asia-Pacific as a critical driver of global excipient supply, where innovation and scalability converge to meet growing demand.

Highlighting Leading Players, Strategic Collaborations, and Technological Advancements Shaping the Competitive Pharmaceutical Excipent Landscape

Leading organizations in the excipient arena have pursued diverse strategies to strengthen their competitive position and capture value across the pharmaceutical value chain. Strategic mergers and acquisitions have enabled them to broaden their product portfolios, attaining capabilities in both traditional and emerging excipient categories. Simultaneously, technology alliances with academic laboratories and specialized chemical manufacturers have accelerated innovation, allowing companies to co-develop advanced carriers tailored for complex biologics and novel delivery platforms.

In addition to collaboration, prominent firms are investing in state-of-the-art research centers and pilot facilities to advance excipient characterization and scale-up processes. These investments underpin the development of next-generation materials, such as biodegradable polymers and multifunctional granulation excipients, designed to meet stringent regulatory and environmental requirements. Furthermore, partnerships with contract development and manufacturing organizations have enabled flexible capacity expansion, ensuring responsiveness to fluctuating demand and facilitating rapid market entry for new therapeutic formulations.

Sustainability commitments have become integral to corporate strategies, with industry leaders introducing solvent-free production methods and sourcing renewable feedstocks. Digital transformation initiatives are also reshaping operations, as companies implement real-time monitoring systems, predictive quality analytics, and supply chain traceability platforms. By embracing these trends, key players are not only reinforcing their market leadership but also setting new benchmarks for quality, reliability, and environmental stewardship within the pharmaceutical excipient sector.

The competitive landscape is further enriched by emerging specialty companies that focus on niche excipient applications and tailored formulation solutions. These agile enterprises leverage deep technical expertise and customer-centric development models to address unmet needs in areas such as pediatric formulations, targeted release systems, and personalized medicine. Their presence stimulates continuous innovation and keeps established players attentive to evolving market demands.

Strategic Action Points and Best Practice Guidelines for Industry Leaders to Navigate Future Challenges and Leverage Excipent Innovations

To thrive in a landscape characterized by rapid technological advancements and shifting regulatory expectations, industry leaders should prioritize investment in excipient innovation platforms. By adopting integrated discovery tools, such as high-throughput screening and molecular modeling, organizations can accelerate the identification of functional carriers that address specific stability, solubility, or release challenges. Emphasizing cross-functional collaboration between material scientists, formulation experts, and regulatory affairs teams will streamline development timelines and enhance the likelihood of successful regulatory review.

Strengthening supply chain resilience is another critical recommendation. Establishing diversified sourcing strategies, including dual suppliers and regional partnerships, will mitigate risks associated with trade policy changes and logistical disruptions. Firms should also implement digital supply chain management systems that offer end-to-end visibility, enabling proactive identification of potential bottlenecks and real-time decision-making. Collaboration with logistics providers and participation in industry consortia can further reinforce continuity and ensure rapid response to unforeseen events.

Finally, embedding sustainability and quality by design principles within excipient development processes will create long-term competitive advantages. Organizations are encouraged to adopt life cycle assessment methodologies to evaluate environmental impacts, prioritize renewable raw materials, and invest in solvent-free manufacturing techniques. Concurrently, integrating risk-based quality frameworks will foster robust product performance and regulatory compliance. By aligning these strategic priorities, industry leaders can deliver patient-centric formulations, maintain regulatory excellence, and position themselves at the forefront of the evolving pharmaceutical excipient ecosystem.

Detailed Explanation of the Research Approach, Data Sources, Validation Techniques, and Analytical Frameworks Employed in the Study

The research methodology underpinning this study combined a multi-tiered approach to ensure comprehensive coverage of the pharmaceutical excipient landscape. Initial phases involved rigorous secondary research, leveraging authoritative scientific publications, regulatory guidelines, patent analyses, and industry white papers to establish foundational insights. This desk-based work provided contextual background on excipient classifications, emerging technologies, and policy frameworks that shape the sector.

Subsequent primary research efforts included in-depth interviews with key stakeholders, such as formulation scientists, quality assurance managers, procurement specialists, and regulatory experts. These discussions yielded qualitative perspectives on operational challenges, innovation priorities, and supply chain strategies. Insights from these stakeholders were triangulated with secondary data to validate emerging trends and identify areas of strategic importance.

Analytical processes integrated both qualitative and quantitative assessments. Data points were evaluated through comparative analysis, thematic coding, and scenario mapping to elucidate drivers, barriers, and potential opportunities within the excipient domain. Validation techniques included peer review by subject matter experts and consistency checks against external benchmarks. This rigorous framework ensured that conclusions and recommendations accurately reflect the current state and future trajectories of the pharmaceutical excipient market.

Acknowledging the dynamic nature of the excipient sector, continual data updates and iterative feedback loops were incorporated throughout the study. Periodic validation checkpoints ensured alignment with the latest regulatory changes, technological breakthroughs, and supply chain developments. This approach reinforced the robustness and relevance of the insights, enabling stakeholders to make informed decisions within an ever-evolving environment.

Synthesizing Key Findings and Strategic Implications for Stakeholders in the Pharmaceutical Excipent Arena to Drive Informed Decision-Making

In summary, the pharmaceutical excipient landscape stands at the intersection of innovation, regulatory rigor, and supply chain resilience. Excipients have transcended their traditional inert roles to become strategic enablers of stability, bioavailability, and patient-centric design across diverse dosage forms. Technological advances such as artificial intelligence, continuous manufacturing, and sustainable production methods are driving a new wave of functional carriers that align with evolving therapeutic modalities.

Trade policy shifts, particularly recent tariff adjustments, have highlighted the importance of diversified sourcing strategies and digital supply chain visibility. Organizations that proactively recalibrate procurement frameworks and forge regional partnerships have demonstrated greater continuity and cost efficiency. Segmentation analysis underscores the breadth of excipient categories, from inorganic minerals to complex organic carriers, all of which must be matched to specific formulation requirements, end-user needs, and distribution pathways.

Regional dynamics reveal unique opportunities and challenges across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each characterized by distinct regulatory frameworks, manufacturing capacities, and innovation priorities. Key players are responding through strategic collaborations, capacity expansions, and sustainability initiatives. By integrating the actionable recommendations outlined in this summary-focusing on innovation platforms, supply chain resilience, and quality by design-stakeholders can navigate uncertainties and position themselves at the forefront of the pharmaceutical excipient ecosystem. This comprehensive understanding serves as a guide for informed decision-making and long-term strategic planning.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Advancements in silica-based glidants optimizing powder flow for high-speed tablet production under GMP conditions
  • 5.2. Shift towards plant-based and clean-label excipients as patient demand for natural formulations increases
  • 5.3. Adoption of co-processed excipients driving direct compression formulation efficiencies in tablet manufacturing
  • 5.4. Integration of real-time analytical technologies in excipient manufacturing for continuous process verification
  • 5.5. Rising regulatory focus on quality by design to standardize excipient production across global markets
  • 5.6. Emergence of biodegradable polymer excipients to meet sustainability targets and reduce environmental impact
  • 5.7. Supply chain diversification strategies to mitigate raw material shortages in pharmaceutical excipient markets

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Pharmaceutical Excipient Market, by Type

  • 8.1. Introduction
  • 8.2. Inorganic
    • 8.2.1. Calcium Carbonate
    • 8.2.2. Calcium Phosphate
    • 8.2.3. Calcium Sulfate
    • 8.2.4. Halites
    • 8.2.5. Metal Oxides
  • 8.3. Organic
    • 8.3.1. Carbohydrates
      • 8.3.1.1. Cellulose
      • 8.3.1.2. Starch
      • 8.3.1.3. Sugars
    • 8.3.2. Oleochemicals
      • 8.3.2.1. Fatty Alcohols
      • 8.3.2.2. Glycerin
      • 8.3.2.3. Mineral Stearates
    • 8.3.3. Petrochemicals
      • 8.3.3.1. Acrylic Polymers
      • 8.3.3.2. Glycols
      • 8.3.3.3. Mineral Hydrocarbons
      • 8.3.3.4. Povidones
    • 8.3.4. Proteins

9. Pharmaceutical Excipient Market, by Formulation

  • 9.1. Introduction
  • 9.2. Oral Formulations
    • 9.2.1. Hard Gelatin Capsules
    • 9.2.2. Liquid Formulations
    • 9.2.3. Soft Gelatin Capsules
    • 9.2.4. Tablets
  • 9.3. Parenteral Formulations
  • 9.4. Topical Formulations

10. Pharmaceutical Excipient Market, by Function

  • 10.1. Introduction
  • 10.2. Binders
  • 10.3. Coating Agents
  • 10.4. Colorants
  • 10.5. Disintegrants
  • 10.6. Emulsifying Agents
  • 10.7. Fillers & Diluents
  • 10.8. Flavoring Agents & Sweeteners
  • 10.9. Lubricants & Glidants
  • 10.10. Preservatives
  • 10.11. Suspending & Viscosity Agents

11. Pharmaceutical Excipient Market, by End-User

  • 11.1. Introduction
  • 11.2. Biopharmaceutical Companies
  • 11.3. Contract Manufacturing Organizations
  • 11.4. Pharmaceutical Companies
  • 11.5. Research Laboratories

12. Pharmaceutical Excipient Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Offline
  • 12.3. Online

13. Americas Pharmaceutical Excipient Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Pharmaceutical Excipient Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Pharmaceutical Excipient Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. ABITEC Corporation
    • 16.3.2. Actylis
    • 16.3.3. Archer Daniels Midland Company
    • 16.3.4. ARMOR PROTEINES S.A.S. by Savencia Group
    • 16.3.5. Asahi Kasei Corporation
    • 16.3.6. Ashland Inc.
    • 16.3.7. BASF SE
    • 16.3.8. BIOGRUND GmbH
    • 16.3.9. Chemische Fabrik Budenheim KG by Geschwister Oetker Beteiligungen KG
    • 16.3.10. Clariant AG
    • 16.3.11. Colorcon Inc.
    • 16.3.12. Corel Pharma Chem Private Limited
    • 16.3.13. Croda International Plc
    • 16.3.14. Darling Ingredients, Inc.
    • 16.3.15. DFE Pharma GmbH & Co KG by Royal FrieslandCampina N.V.
    • 16.3.16. DuPont de Nemours, Inc.
    • 16.3.17. Evonik Industries AG
    • 16.3.18. Fuji Chemical Industries Co., Ltd.
    • 16.3.19. GATTEFOSSE SAS
    • 16.3.20. Innophos Holdings, Inc. by Iris Parent LLC
    • 16.3.21. International Flavors & Fragrances Inc.
    • 16.3.22. JRS PHARMA GmbH + Co. KG
    • 16.3.23. Kerry Group P.L.C.
    • 16.3.24. Lipoid GmbH
    • 16.3.25. Lubrizol Corporation
    • 16.3.26. L'AIR LIQUIDE S.A.
    • 16.3.27. Mallinckrodt plc
    • 16.3.28. MEGGLE GmbH & Co. KG
    • 16.3.29. Merck KGaA
    • 16.3.30. Nagase & Co., Ltd.
    • 16.3.31. Nipon Soda Co., Ltd.
    • 16.3.32. NOF Corporation
    • 16.3.33. Omya International AG
    • 16.3.34. Peter Greven GmbH & Co. KG
    • 16.3.35. Roquette Freres S.A.
    • 16.3.36. Shin-Etsu Chemical Co., Ltd.
    • 16.3.37. Solvay S.A.
    • 16.3.38. SPI Pharma, Inc.
    • 16.3.39. Sumitomo Seika Chemicals Company, Limited
    • 16.3.40. Thermo Fisher Scientific Inc.
    • 16.3.41. Vanderbilt Minerals LLC

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. PHARMACEUTICAL EXCIPIENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. PHARMACEUTICAL EXCIPIENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. PHARMACEUTICAL EXCIPIENT MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. PHARMACEUTICAL EXCIPIENT MARKET: RESEARCHAI
  • FIGURE 26. PHARMACEUTICAL EXCIPIENT MARKET: RESEARCHSTATISTICS
  • FIGURE 27. PHARMACEUTICAL EXCIPIENT MARKET: RESEARCHCONTACTS
  • FIGURE 28. PHARMACEUTICAL EXCIPIENT MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. PHARMACEUTICAL EXCIPIENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CALCIUM CARBONATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CALCIUM CARBONATE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CALCIUM PHOSPHATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CALCIUM PHOSPHATE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CALCIUM SULFATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CALCIUM SULFATE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY HALITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY HALITES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY METAL OXIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY METAL OXIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CELLULOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CELLULOSE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY STARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY STARCH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY SUGARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY SUGARS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FATTY ALCOHOLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FATTY ALCOHOLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY GLYCERIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY GLYCERIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY MINERAL STEARATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY MINERAL STEARATES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ACRYLIC POLYMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ACRYLIC POLYMERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY GLYCOLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY GLYCOLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY MINERAL HYDROCARBONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY MINERAL HYDROCARBONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY POVIDONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY POVIDONES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PROTEINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY HARD GELATIN CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY HARD GELATIN CAPSULES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY SOFT GELATIN CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY SOFT GELATIN CAPSULES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PARENTERAL FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PARENTERAL FORMULATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY BINDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY BINDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY COATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY COATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY COLORANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY COLORANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISINTEGRANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISINTEGRANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY EMULSIFYING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY EMULSIFYING AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FILLERS & DILUENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FILLERS & DILUENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FLAVORING AGENTS & SWEETENERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FLAVORING AGENTS & SWEETENERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY LUBRICANTS & GLIDANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY LUBRICANTS & GLIDANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PRESERVATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PRESERVATIVES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY SUSPENDING & VISCOSITY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY SUSPENDING & VISCOSITY AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 121. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2025-2030 (USD MILLION)
  • TABLE 123. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2025-2030 (USD MILLION)
  • TABLE 125. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2025-2030 (USD MILLION)
  • TABLE 127. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 129. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 131. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 133. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 135. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2025-2030 (USD MILLION)
  • TABLE 137. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 139. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 141. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 143. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 145. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2018-2024 (USD MILLION)
  • TABLE 146. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2025-2030 (USD MILLION)
  • TABLE 149. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2018-2024 (USD MILLION)
  • TABLE 150. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 163. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 165. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 166. UNITED STATES PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 167. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2018-2024 (USD MILLION)
  • TABLE 170. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2025-2030 (USD MILLION)
  • TABLE 171. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2018-2024 (USD MILLION)
  • TABLE 172. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2025-2030 (USD MILLION)
  • TABLE 173. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2018-2024 (USD MILLION)
  • TABLE 174. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2025-2030 (USD MILLION)
  • TABLE 175. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 176. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 177. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 178. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 179. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 180. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 181. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 182. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 183. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2018-2024 (USD MILLION)
  • TABLE 184. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2025-2030 (USD MILLION)
  • TABLE 185. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 186. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 187. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. CANADA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 189. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2018-2024 (USD MILLION)
  • TABLE 192. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2025-2030 (USD MILLION)
  • TABLE 193. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2018-2024 (USD MILLION)
  • TABLE 194. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2025-2030 (USD MILLION)
  • TABLE 195. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2018-2024 (USD MILLION)
  • TABLE 196. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2025-2030 (USD MILLION)
  • TABLE 197. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 198. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 199. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 200. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 201. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 202. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 203. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 204. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 205. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2018-2024 (USD MILLION)
  • TABLE 206. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2025-2030 (USD MILLION)
  • TABLE 207. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 208. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 209. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. MEXICO PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 211. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 213. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2018-2024 (USD MILLION)
  • TABLE 214. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2025-2030 (USD MILLION)
  • TABLE 215. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2018-2024 (USD MILLION)
  • TABLE 216. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2025-2030 (USD MILLION)
  • TABLE 217. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2018-2024 (USD MILLION)
  • TABLE 218. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2025-2030 (USD MILLION)
  • TABLE 219. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 220. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 221. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 222. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 223. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 224. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 225. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 226. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 227. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2018-2024 (USD MILLION)
  • TABLE 228. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2025-2030 (USD MILLION)
  • TABLE 229. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 230. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 231. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. BRAZIL PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 233. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 235. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2018-2024 (USD MILLION)
  • TABLE 236. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2025-2030 (USD MILLION)
  • TABLE 237. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2018-2024 (USD MILLION)
  • TABLE 238. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2025-2030 (USD MILLION)
  • TABLE 239. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2018-2024 (USD MILLION)
  • TABLE 240. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2025-2030 (USD MILLION)
  • TABLE 241. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 242. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 243. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 244. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 245. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 246. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 247. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 248. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 249. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2018-2024 (USD MILLION)
  • TABLE 250. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2025-2030 (USD MILLION)
  • TABLE 251. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 252. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 253. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. ARGENTINA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2025-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2025-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2025-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2025-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2025-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2018-2024 (USD MILLION)
  • TABLE 284. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2025-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2025-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 291. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 293. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 295. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2018-2024 (USD MILLION)
  • TABLE 296. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2025-2030 (USD MILLION)
  • TABLE 297. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 298. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 299. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. UNITED KINGDOM PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 301. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 303. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2018-2024 (USD MILLION)
  • TABLE 304. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY INORGANIC, 2025-2030 (USD MILLION)
  • TABLE 305. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2018-2024 (USD MILLION)
  • TABLE 306. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORGANIC, 2025-2030 (USD MILLION)
  • TABLE 307. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2018-2024 (USD MILLION)
  • TABLE 308. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY CARBOHYDRATES, 2025-2030 (USD MILLION)
  • TABLE 309. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 310. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY OLEOCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 311. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2018-2024 (USD MILLION)
  • TABLE 312. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY PETROCHEMICALS, 2025-2030 (USD MILLION)
  • TABLE 313. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 314. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 315. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 316. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY ORAL FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 317. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2018-2024 (USD MILLION)
  • TABLE 318. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY FUNCTION, 2025-2030 (USD MILLION)
  • TABLE 319. GERMANY PHARMACEUTICAL EXCIPIENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 320. GERMAN